Tag: Boston Scientific

VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...

Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
innovation in peripheral technologies to drives Boston Scientific

Michael Jaff joins Boston Scientific to drive innovation in peripheral technologies

Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role,...

CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...

NOTE: ONLY intended for healthcare professionals outside of the USA and France. Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...

Only Eluvia Uses a Polymer for Controlled, Targeted Delivery of the...

Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of...

Hear the latest thoughts on paclitaxel from global experts: Their current...

 Following the latest information presented at the Charing Cross (CX) International Symposium related to the meta-analysis of paclitaxel-coated devices (Katsanos et al), hear from a...

Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses

Boston Scientific has announced results from sub-analyses of the IMPERIAL clinical trial for the Eluvia Drug-Eluting Vascular Stent System at the 41st Charing Cross...
medtronic

Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical...

Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...

Boston Scientific announces recommended offer to acquire BTG

Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...

Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study

Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...

Eluvia outperforms Zilver PTX in IMPERIAL 12-month results

The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...

SAVAL trial of new below-the-knee drug-eluting stent begins

The first patient has been enrolled in the SAVAL pivotal trial to evaluate clinical outcomes of the SAVAL below-the-knee (BTK) drug-eluting stent system (Boston...

Boston Scientific to buy cerebral protection system company

Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system. The device is used...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

Eluvia paclitaxel-eluting vascular stent system demonstrates promising three-year freedom from revascularisation

The three-year results from the MAJESTIC trial for Boston Scientific’s Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe...

Clearing the clot: New horizons in deep vein thrombosis treatment

In this supplement: --Life post-ATTRACT: The new challenge of DVT treatment --The future of DVT intervention in Europe: what needs to happen next --"With...

Positive results for Boston Scientific Ranger paclitaxel-coated PTA balloon catheter

Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017...

Endovenous laser therapy of saphenous vein reflux using thulium laser with...

In this clinical study the one-year results of the endovenous laser therapy (ELT) application of 1,940nm laser (Vela XL, Boston Scientific) with respect to...

Stefan Müller-Hülsbeck: The current drug-eluting stent landscape

In this interview, Stefan Müller-Hülsbeck, Diako Hospital, Flensburg, Germany, explains the implications of fresh two-year drug-eluting stent data from the MAJESTIC trial, and discusses...

Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent

The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery...

Veniti closes on US$25m from Boston Scientific

Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial...

Promising findings for novel drug-eluting peripheral stent

A new animal study, presented at EuroPCR (17–20 May, Paris), indicates that a novel, fluoropolymer-coated, self-expanding, paclitaxel-eluting peripheral stent (Eluvia, Boston Scientific) is associated...